Drugs / INhance
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04677712 Comparator | Dec 2020 → Jun 2021 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INhance | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04677712 ↗ |
| Route | Topical | “used INhance Post-injection Serum topically” NCT04677712 ↗ |